ACADIA Pharmaceuticals Inc.
ACAD
$16.12
-$0.50-3.01%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 31.85% | 47.06% | 61.65% | 56.43% | 40.45% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 31.85% | 47.06% | 61.65% | 56.43% | 40.45% |
| Cost of Revenue | -2.08% | -10.24% | 45.08% | 30.36% | 5.79% |
| Gross Profit | 71.89% | 137.46% | 81.27% | 95.11% | 129.00% |
| SG&A Expenses | 16.47% | 13.87% | 14.40% | 10.62% | 10.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.35% | 2.01% | 27.91% | 19.58% | 7.96% |
| Operating Income | 235.16% | 182.35% | 117.90% | 97.21% | 67.18% |
| Income Before Tax | 605.67% | 203.85% | 143.20% | 110.22% | 76.09% |
| Income Tax Expenses | 208.53% | -52.34% | 208.89% | 12,880.47% | 304.98% |
| Earnings from Continuing Operations | 469.50% | 186.36% | 127.58% | 98.83% | 71.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 469.50% | 186.36% | 127.58% | 98.83% | 71.62% |
| EBIT | 235.16% | 182.35% | 117.90% | 97.21% | 67.18% |
| EBITDA | 269.64% | 192.97% | 127.58% | 103.74% | 69.39% |
| EPS Basic | 461.27% | 185.19% | 126.81% | 98.71% | 71.79% |
| Normalized Basic EPS | 320.83% | 206.73% | 136.22% | 106.39% | 74.27% |
| EPS Diluted | 448.69% | 183.42% | 125.14% | 97.91% | 71.00% |
| Normalized Diluted EPS | 318.28% | 206.07% | 135.50% | 105.93% | 74.07% |
| Average Basic Shares Outstanding | 1.24% | 1.41% | 1.51% | 1.47% | 1.24% |
| Average Diluted Shares Outstanding | 1.16% | 1.83% | 1.90% | 2.26% | 1.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
